Last edition
News about "argenx "
argenx Updates Phase 3 UNITY Trial of Efgartigimod
argenx plans to stop its phase 3 UNITY study of efgartigimod SC in Sjögren’s disease following an IDMC recommendation based on interim analysis.
Argenx | 09/10/2026 | By News Bureau | 121
argenx Reports Positive Phase 3 ALKIVIA Results for Efgartigimod in Autoimmune Myositis
argenx reports positive Phase 3 ALKIVIA results for efgartigimod in autoimmune myositis, meeting the primary endpoint with sustained patient improvements.
Argenx | 17/08/2026 | By News Bureau | 107
argenx to Acquire Forte Biosciences
argenx will acquire Forte Biosciences to add the first-in-class anti-CD122 antibody FB102, expanding its immunology pipeline.
Argenx | 27/07/2026 | By News Bureau | 172
argenx Secures FDA Approval for VYVGART Hytrulo Co-Formulated with ENHANZE
Halozyme Therapeutics has announced that argenx has received US Food and Drug Administration (FDA) approval for VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) co-formulated with ENHANZE, Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, for the treatment of adults with chronic inflammatory demyelinating polyneuropathy.
Argenx | 24/06/2024 | By Aishwarya | 787
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy